Memantine Protects Rats Treated with Intrathecal Methotrexate from Developing Spatial Memory Deficits

Abstract

Purpose To test whether memantine can prevent methotrexate-induced cognitive deficits in a preclinical model. Experimental Design After noting that methotrexate exposure induces prolonged elevations of the glutamate analog homocysteic acid (HCA) within cerebrospinal fluid, we tested whether intrathecal injection of HCA would produce memory deficits similar to those observed after intrathecal methotrexate. We then tested whether memantine, an antagonist of the N-methyl-D-aspartate (NMDA) subclass of glutamate receptors, could protect animals treated with clinically relevant doses of intrathecal methotrexate against developing memory deficits. Finally, we asked whether memantine affected this pathway beyond inhibiting the NMDA receptor by altering expression of the NMDA receptor or affecting concentrations of HCA or glutamate within the central nervous system. Results Four intrathecal doses of methotrexate induced deficits in spatial memory, persisting at least one month following the final injection. Intrathecal HCA was sufficient to reproduce this deficit. Concurrent administration of memantine during the period of methotrexate exposure was protective, decreasing the incidence of methotrexate-induced spatial memory deficits from 56% to 20% (P < 0.05). Memantine neither altered expression of NMDA receptors within the hippocampus nor blunted the methotrexate-induced increases in glutamate or HCA. Conclusions Excitotoxic glutamate analogs including HCA contribute to cognitive deficits observed after intrathecal methotrexate. Memantine, an NMDA receptor antagonist, reduces the incidence of cognitive deficits in rats treated with intrathecal methotrexate, and may therefore benefit patients with cancer receiving similar treatment.

Neuro Protective Effects of Wheat Germ Oil on the Brain Inflammation Induced by Methotrexate in Mice

“…These findings revealed that MTX induced oxidative stress in the nervous system causing brain injury. This result was also observed in previous literature which declared that (ROS) generation altered neurotransmission 68 and/or induced structural brain alterations 13 while also causing mitochondrial damage which in turn causes rapid degeneration of the cells 69 and plays an important role in pathogenesis of neurodegenerative disorders, cancer and aging [21][22][23] . In addition, 57 revealed that methotrexate induced changes in neuroinflammatory markers and cellular proliferation, along with structural changes in the corpus callosum in the brain.…”

Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia

“…Finally, emerging preclinical and clinical data are identifying therapeutic interventions that might protect against specific TRTs, such as dexrazoxane to prevent cardiotoxicity [100], cholesterol lowering agents to prevent bone toxicity [101,102], and memantine to prevent neurotoxicity [103]. Clinical trials testing the efficacy of these strategies might target those children with ALL at greatest risk, as determined by their individual genetic makeup.…”

Loss of Gas6 and Axl signaling results in extensive axonal damage, motor deficits, prolonged neuroinflammation, and less remyelination following cuprizone exposure

“…Results are also shown as the proportion of subjects passing and failing where passing criteria is a 55% preference score. This rationale and validation of this criterion has been detailed elsewhere (Cole et al, ; Li, Vijayanathan, Gulinello, & Cole, ; Li, Vijayanathan, Gulinello, & Cole, ). There was no significant difference in motor performance of naïve WT and DKO mice on the balance beams, negative geotaxis, and object placement assays.…”